Delphi Diagnostics Appoints Eric Lindquist as Chief Financial Officer
Delphi Diagnostics has appointed Eric Lindquist as Chief Financial Officer, effective April 1, 2026. Lindquist, with extensive experience in oncology and life sciences, will lead financial strategy as the company advances its Endocrine Activity Index® (EAI™) test for breast cancer treatment. He previously held leadership roles in various pharmaceutical and diagnostics firms, including InnoSIGN and Celcuity.
Experienced oncology and life sciences executive to lead financial strategy and support the next phase of growth For a PDF of this release, please click here HOUSTON, May 19, 2026 /PRNewswire/ — Delphi Diagnostics today announced the appointment of Eric Lindquist as Chief Financial…